Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Forecast With Analysis Of Industry Progress Through 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Change Between 2026 And 2030?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market has experienced rapid expansion in recent years. This market is projected to expand from $13.29 billion in 2025 to $17.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 28.1%. Historically, this growth can be attributed to factors such as improved disease awareness among cardiologists, increased diagnosis of rare cardiomyopathies, the availability of targeted pharmacological therapies, the expansion of specialty cardiac care centers, and progress in genetic screening technologies.
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market is projected to experience substantial expansion over the upcoming years, reaching a size of $45.09 billion by 2030, progressing at a compound annual growth rate (CAGR) of 27.6%. This anticipated growth during the forecast period is fueled by several factors, including the broadened application of precision medicine, the increasing creation of next-generation gene-silencing treatments, elevated funding in drug development for rare diseases, improved patient access to sophisticated cardiac diagnostic tools, and a heightened emphasis on therapies that modify disease progression. Key trends expected during this period involve the greater uptake of transthyretin stabilizer therapies, the growing utilization of rnAI-based treatment methods, an intensified focus on prompt diagnosis and disease surveillance, the diversification of personalized treatment plans, and boosted investments in research for rare cardiac conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
What Important Drivers Are Powering The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth?
The increasing incidence of chronic illnesses is anticipated to drive expansion in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market moving forward. These are enduring health issues that develop gradually and endure for at least a year, frequently necessitating ongoing medical attention. The growing occurrence of chronic ailments stems from elements like an aging demographic, inactive routines, poor nutritional habits, rising levels of obesity, and exposure to environmental contaminants. Treatment for transthyretin amyloid cardiomyopathy works by stabilizing transthyretin, decreasing the accumulation of amyloid, enhancing cardiac performance, and easing symptoms to more effectively manage associated chronic disorders. For example, in April 2025, data from the Centers for Disease Control and Prevention (CDC), a US-based federal agency, indicated that in 2023, around 194 million U.S. adults, representing 76.4% of the population, reported suffering from at least one chronic ailment. This prevalence stood at 59.5% for young adults, 78.4% for midlife adults, and 93.0% for older adults. Consequently, the expanding occurrence of chronic diseases is propelling the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
How Are Different Segment Groups Identified Within The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The transthyretin amyloid cardiomyopathy (attr-cm) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Which Trends Are Contributing To Changes In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Which Firms Are Competing In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major companies operating in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market are Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Intellia Therapeutics Inc, SOM Biotech S L, Ionis Pharmaceuticals Inc, Eidos Therapeutics Inc, Prothena Corporation plc, Neurimmune Holding AG, Corino Therapeutics Inc, CRISPR Therapeutics AG, YolTech Therapeutics Co Ltd, Silence Therapeutics plc, Akcea Therapeutics Inc
Access The Complete Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report:
Which Region Is The Primary Market For The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (attr-cm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp
Browse Through More Reports Similar to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market 2026, By The Business Research Company
Hypertrophic Cardiomyopathy Treatment Global Market Report 2026
Hypertrophic Cardiomyopathy Hcm Therapeutics Global Market Report 2026
Cardiometabolic Diseases Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
